The efficacy of neoadjuvant therapy (NT) versus surgery first (SF) for pancreatic ductal
adenocarcinoma (PDAC) remains controversial. A random-effects meta-analysis of only …

Introduction Preoperative autophagy inhibition with hydroxychloroquine (HCQ) in
combination with gemcitabine in pancreatic adenocarcinoma (PDAC) has been shown to be …

Despite improvements in multidisciplinary treatments, survival of pancreatic cancer (PC)
patients remains dismal. Studies dealing with early onset pancreatic cancer (EOPC) patients …

Background: Current guidelines support either immediate surgical resection or neoadjuvant
therapy (NT) for patients with resectable pancreatic ductal adenocarcinoma (PDAC) …

Background With limited evidence, the benefit of adjuvant chemotherapy (AT) after
completion of neoadjuvant chemotherapy (NT) and surgical resection for patients with …

Pancreatic ductal adenocarcinoma is an aggressive cancer with high recurrence rates
following surgical resection. While adjuvant chemotherapy improves survival, a significant …

Pancreatic cancer is a malignant disease with a dismal prognosis. While neoadjuvant
therapy has shown promise in the treatment of pancreatic cancer, its role remains a subject …

Abstract Background and Objectives Neoadjuvant chemotherapy (NAT) for pancreatic
adenocarcinoma (PDAC) is increasingly being utilized. However, a significant number of …

Background Margin-negative resection is the only cure for pancreatic cancer. However, para-
aortic lymph node metastasis is considered a contraindication to curative resection in …

Background Despite controversy regarding the role of neoadjuvant chemotherapy (NAC) in
pancreatic adenocarcinoma, nearly half of resected patients do not receive chemotherapy …